Institution
Foundation Medicine
About: Foundation Medicine is a based out in . It is known for research contribution in the topics: Cancer & Targeted therapy. The organization has 430 authors who have published 1085 publications receiving 41789 citations.
Topics: Cancer, Targeted therapy, Lung cancer, Breast cancer, KRAS
Papers
More filters
••
Baylor College of Medicine1, Van Andel Institute2, University of North Carolina at Chapel Hill3, University of Texas MD Anderson Cancer Center4, Foundation Medicine5, Catalan Institution for Research and Advanced Studies6, University of Arkansas for Medical Sciences7, Nationwide Children's Hospital8
TL;DR: Analysis of tumor biopsies from an unbiased cohort of 111 exceptional responder patients revealed synthetic lethal relationships that may be exploited therapeutically and rare genetic lesions that favor therapeutic success, while also providing a wealth of testable hypotheses regarding oncogenic mechanisms that may influence the response to cancer therapy.
55 citations
••
TL;DR: Afatinib/cetuximab shows encouraging clinical efficacy in pts with AR to erlotinib or gefitinib, demonstrating that many EGFR mt NSCLCs continue to depend on ErbB signalling for survival.
55 citations
••
55 citations
••
TL;DR: The conclusion that comprehensive genomic profiling should be regularly applied to these disorders at diagnosis, and can positively impact clinical care is supported, is supported.
Abstract: Many patients with histiocytic disorders such as Langerhans cell histiocytosis (LCH) or Erdheim-Chester disease (ECD) have treatment-refractory disease or suffer recurrences. Recent findings of gene mutations in histiocytoses have generated options for targeted therapies. We sought to determine the utility of prospective sequencing of select genes to further characterize mutations and identify targeted therapies for patients with histiocytoses. Biopsies of 72 patients with a variety of histiocytoses underwent comprehensive genomic profiling with targeted DNA and RNA sequencing. Fifteen patients (21%) carried the known BRAF V600E mutation, and 11 patients (15%) carried various mutations in MAP2K1, which we confirm induce constitutive activation of extracellular signal-regulated kinase (ERK) and were sensitive to inhibitors of mitogen-activated protein kinase kinase (MEK, the product of MAP2K1). We also identified recurring ALK rearrangements, and 4 LCH patients with an uncommon in-frame deletion in BRAF (N486_P490del or N486_T491>K), resulting in constitutive activation of ERK with resistance to V600E-specific inhibitors. We subsequently describe clinical cases where patients with aggressive multisystem LCH experience dramatic and sustained responses to monotherapy with either dabrafenib or trametinib. These findings support our conclusion that comprehensive genomic profiling should be regularly applied to these disorders at diagnosis, and can positively impact clinical care.
54 citations
••
TL;DR: This article states that fusion protein-related and other immunohistochemical markers can have a high specificity for fusion sarcomas and methods to detect gene fusions include next-generation sequencing panels, anchored multiplex polymerase chain reaction systems to detect partner for a known fusion gene, and comprehensive RNA sequencing to detect virtually all genes.
54 citations
Authors
Showing all 430 results
Name | H-index | Papers | Citations |
---|---|---|---|
Bartolome R. Celli | 118 | 650 | 63423 |
Vincent A. Miller | 105 | 647 | 65822 |
Vera J. Suman | 76 | 294 | 35533 |
Adam Brufsky | 74 | 460 | 27570 |
Jeffrey S. Ross | 70 | 347 | 21334 |
Philip J. Stephens | 69 | 236 | 29559 |
Kai Wang | 69 | 1095 | 21841 |
Siraj M. Ali | 65 | 463 | 25639 |
Jeffrey S. Ross | 59 | 343 | 20600 |
Roman Yelensky | 57 | 164 | 15073 |
Doron Lipson | 57 | 180 | 17014 |
Garrett M. Frampton | 55 | 215 | 22373 |
Geoffrey R. Oxnard | 54 | 245 | 14325 |
Brian M. Alexander | 50 | 264 | 9200 |
Jeffrey P. Gregg | 46 | 107 | 4882 |